澳大利亚60岁以下人群接种阿斯利康COVID-19疫苗后血栓伴血小板减少综合征的风险获益分析
该研究针对澳大利亚18-59岁人群,比较接种阿斯利康ChAdOx1 nCoV-19疫苗与感染COVID-19的风险,并将血栓伴血小板减少综合征(TTS)发生率与其他因罕见不良事件而调整政策的疫苗比较。结果显示TTS报告率约为3/10万剂,若80%该人群接种,估计TTS病例347例、疫苗相关死亡17-153例;过去15个月该人群COVID-19死亡20例,而60岁以上890例。结论认为对低COVID-19死亡风险的年轻成人,疫苗潜在风险可能超过获益。
要点
- TTS报告率约3/10万剂,与其它促政策调整的疫苗罕见不良事件率相当。
- 若80%的18-59岁人群接种,估计TTS病例347例,疫苗相关死亡17-153例。
- 年轻成人COVID-19死亡风险低,潜在疫苗风险可能超过获益。
核心结论
- 在澳大利亚,对COVID-19死亡风险低的年轻成人,阿斯利康ChAdOx1 nCoV-19疫苗的潜在风险可能超过获益。
研究设计与样本
- 针对澳大利亚18-59岁人群的风险获益分析,比较接种疫苗与感染COVID-19的风险,并将TTS发生率与其他因罕见不良事件调整政策的疫苗比较。
主要发现
- TTS报告率为3/100,000剂接种,许多国家报告高致死率。
- 当前及未来最坏情景下,12个月COVID-19死亡数范围为0至417例。
- 过去15个月,60岁以下人群COVID-19死亡20例,60岁以上890例。
- 若80%的18-59岁成人接种,估计TTS病例347例,疫苗相关死亡17至153例。
关键数值与推荐
- TTS报告率为3/100,000剂接种。
- 若80%的18-59岁成人接种,估计TTS病例347例,疫苗相关死亡17至153例。
- 过去15个月,60岁以下COVID-19死亡20例,60岁以上890例。
临床怎么用
- 对年轻成人接种阿斯利康COVID-19疫苗前,应权衡TTS风险与COVID-19死亡风险。
- 在低COVID-19死亡风险人群中,可考虑调整疫苗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine is associated with Thrombosis with Thrombocytopenia Syndrome (TTS) in 3/100,000 vaccinations with high fatality rates reported in many countries. We conducted a risk-benefit analysis for Australians aged 18-59 years, comparing the risk of vaccination versus infection, and rate of TTS to other vaccines which prompted policy change following rare adverse events - rotavirus, smallpox and oral polio vaccines. COVID-19 deaths over 12 months range from 0 to 417 in current and future worst case scenarios. In the past 15 months 20 COVID-19 deaths occurred in people < 60 years compared to 890 deaths over 60 years. The estimated possible number of TTS cases is 347, with vaccine-related deaths ranging from 17 to 153if 80% of adults 18-59 years are vaccinated. The reported rate of TTS is in the same range as rare but serious adverse events associated with other vaccines that have been subject to policy change. In Australia, the potential risks of the AZD1222 vaccine in younger adults, who are at low risk of dying from COVID-19, may outweigh the benefits.
引用
- MacIntyre CR, Veness B, Berger D, et al. Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia. Vaccine. 2021. PMID: 34272095. doi:10.1016/j.vaccine.2021.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。